Malin Aurell

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis.

A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 02, 2025

MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial.

MYSTERY-HF: Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction: A Phase II Randomized Controlled Trial.

Journal: Circulation

Published: February 12, 2025

Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.

Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.

Journal: Clinical drug investigation

Published: October 14, 2024

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.

Journal: British journal of clinical pharmacology

Published: May 17, 2024

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

Journal: British journal of clinical pharmacology

Published: January 19, 2024

Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Journal: European journal of heart failure

Published: March 01, 2023

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

Journal: American journal of respiratory and critical care medicine

Published: August 19, 2020

INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics.

INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: May 06, 2020

Model-based drug discovery: implementation and impact.

Model-based drug discovery: implementation and impact.

Journal: Drug discovery today

Published: December 19, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026